Disclosed are pharmaceutical compositions comprising compounds of Formula A, and methods of their preparation. Specific examples of compounds of Formula A include: 1-EthyI 3-methyI 2-(3-((3,4-dimethoxyphenethyl)(methyl)amino)propyl)-2-(3,4-dimethoxyphenyl)malonate, Ethyl 4-(2-((4-cyano-4-(3,4-dimethoxyphenyl)-5-methoxy-5-oxopentyl)(methyl)amino)ethyl)benzoate, and Methyl 2-(2-((4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl)(methyl)amino)ethyl)benzoate. The pharmaceutical compositions of Formula A are useful for treating ischemic heart conditions (such as angina), cardiac arrhythmia (such as atrial fibrillation or depolarisations), hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion； and a disease associated with decreased skeletal muscle flow.
